| Withdrawn | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) NCT02082639 | GlaxoSmithKline | Phase 3 |
| Withdrawn | Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Adminis NCT02100618 | GlaxoSmithKline | Phase 3 |
| Completed | Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom NCT01953822 | GlaxoSmithKline | — |
| Completed | Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing NCT01905462 | GlaxoSmithKline | — |
| Completed | Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Chi NCT01627561 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV NCT01418937 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299 NCT01462357 | GlaxoSmithKline | Phase 3 |
| Terminated | Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada NCT01290393 | GlaxoSmithKline | — |
| Completed | Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects NCT01190176 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Yea NCT01381575 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study NCT01190189 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) NCT01277042 | GlaxoSmithKline | Phase 3 |
| Completed | The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Stu NCT01249365 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Viru NCT01031069 | GlaxoSmithKline | Phase 4 |
| Completed | Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination NCT01153906 | GlaxoSmithKline | — |
| Completed | Drug Use Investigation for Cervarix® NCT01187927 | GlaxoSmithKline | — |
| Completed | Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females NCT01101542 | GlaxoSmithKline | — |
| Terminated | Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in NCT00924794 | GlaxoSmithKline | — |
| Completed | Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arab NCT01213459 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subj NCT00996125 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Su NCT00947115 | GlaxoSmithKline | Phase 3 |
| Completed | Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects NCT00937950 | GlaxoSmithKline | Phase 3 |
| Completed | Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316 NCT00929526 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Su NCT00877877 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects. NCT00811798 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Th NCT00849381 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US NCT00799825 | GlaxoSmithKline | Phase 3 |
| Completed | Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subje NCT00779766 | GlaxoSmithKline | Phase 3 |
| Completed | Cervarix Long-term Safety Surveillance NCT01498627 | GlaxoSmithKline | — |
| Completed | Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vac NCT00652938 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) NCT00637195 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Female NCT00586339 | GlaxoSmithKline | Phase 2 |
| Completed | Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America NCT00546078 | GlaxoSmithKline | Phase 2 |
| Completed | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine NCT00578227 | GlaxoSmithKline | Phase 3 |
| Completed | A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-58029 NCT00549900 | GlaxoSmithKline | Phase 1 |
| Completed | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy NCT00552279 | GlaxoSmithKline | Phase 3 |
| Completed | Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in NCT00518336 | GlaxoSmithKline | Phase 2 |
| Completed | Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Age NCT00541970 | GlaxoSmithKline | Phase 1 |
| Completed | Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in NCT00534638 | GlaxoSmithKline | Phase 4 |
| Completed | Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer NCT01207999 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Ag NCT00492544 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix NCT00485732 | GlaxoSmithKline | Phase 3 |
| Completed | Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1 NCT00478621 | GlaxoSmithKline | Phase 1 |
| Completed | Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Fem NCT00456807 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vacc NCT00426361 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gard NCT00423046 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female NCT00369824 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Y NCT00345878 | GlaxoSmithKline | Phase 3 |
| Completed | Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel H NCT00359619 | GlaxoSmithKline | Phase 2 |
| Completed | Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indi NCT00344032 | GlaxoSmithKline | Phase 3 |
| Completed | Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Wom NCT00316693 | GlaxoSmithKline | Phase 2 |
| Completed | Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males. NCT00309166 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 NCT00306241 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age a NCT00294047 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years NCT00290277 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. NCT00250276 | GlaxoSmithKline | Phase 3 |
| Completed | Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Va NCT00231413 | GlaxoSmithKline | Phase 2 |
| Completed | Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologic NCT00196937 | GlaxoSmithKline | Phase 3 |
| Completed | Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/1 NCT00169494 | GlaxoSmithKline | Phase 3 |
| Completed | Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18 NCT00196924 | GlaxoSmithKline | Phase 3 |
| Completed | Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmith NCT00122681 | GlaxoSmithKline | Phase 3 |
| Completed | Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young NCT00120848 | GlaxoSmithKline | Phase 2 |
| Completed | Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Heal NCT00689741 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females NCT00693615 | GlaxoSmithKline | Phase 2 |
| Completed | Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Fema NCT00693966 | GlaxoSmithKline | Phase 2 |